Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revive Therapeutics Ltd (RVV.CN)

Revive Therapeutics Ltd (RVV.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0100 (+100.00%)
RVVTF : 0.0069 (+13.11%)
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

RVV.CN : 0.0100 (+100.00%)
RVVTF : 0.0069 (+13.11%)
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

RVV.CN : 0.0100 (+100.00%)
RVVTF : 0.0069 (+13.11%)
Stocks in play: Revive Therapeutics Ltd

Announced today that the U.S. Food & Drug Administration has granted the Company’s Type C meeting request ...

RVV.CN : 0.0100 (+100.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty...

RVVTF : 0.0069 (+13.11%)
RVV.CN : 0.0100 (+100.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0069 (+13.11%)
RVV.CN : 0.0100 (+100.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company submits Data Access Plan to the FDA to determine potential new clinical endpoints to support Emergency Use Authorization...

RVVTF : 0.0069 (+13.11%)
RVV.CN : 0.0100 (+100.00%)
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.0100 (+100.00%)
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26,...

RVVTF : 0.0069 (+13.11%)
RVV.CN : 0.0100 (+100.00%)
Stocks in play: Revive Therapeutics Ltd

Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...

RVV.CN : 0.0100 (+100.00%)

Barchart Exclusives

Buy Now: 2 Top Dividend Aristocrats With Yields Near 4%
If you love dividends, these two stocks could be good additions to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar